e-Therapeutics plc Director Dealing and Issue of Equity (7036L)
January 04 2023 - 9:15AM
UK Regulatory
TIDMETX
RNS Number : 7036L
e-Therapeutics plc
04 January 2023
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
DIRECTOR DEALING AND ISSUE OF EQUITY
London, UK, 4 January 2023 - e-therapeutics plc (AIM: ETX), the
drug discovery company, announces that o n 4 January 2023,
Professor Trevor Jones (Non-Executive Chairman of the Company)
subscribed for a total of 44,350 new ordinary shares of 0.1p each
in the Company (the "New Ordinary Shares") a t a price of 17.05
pence per
share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 July 2022 to 31 December 2022 in accordance with the agreement entered into with Professor Jones, previously announced o n 5 October 2016, by which Professor Jones agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid is the average of the closing mid-market price for the five business days prior to the date of issue.
Following Admission, Professor Jones will be interested in a
total of 1,167,741 ordinary shares of 0.1p in the Company,
representing approximately 0.20% of the Company's issued share
capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 11 January 2023. The
New Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 582,159,332. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Trevor Jones
-------------------------- --------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------- --------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- --------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name e-therapeutics plc
-------------------------- --------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- --------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- --------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- --------------------------------------------
c) Price(s) and volume(s) 44,350 ordinary shares at a price of 1 7.05
pence per share
-------------------------- --------------------------------------------
d) Aggregated information 44,350 ordinary shares
- Aggregated volume 1 7.05 pence per share
- Price Aggregated value: GBP7,561.76
-------------------------- --------------------------------------------
e) Date of the transaction 4 January 2023
-------------------------- --------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- --------------------------------------------
For further information, please contact:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
James Chandler, VP IR & Communications 125
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary Computational Biology Platform enables the
generation and analysis of biological network models, providing a
novel and mechanistic approach to drug discovery that explicitly
considers the true complexity of biology and makes more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data and information resource. The
Company generates, prioritises and tests millions of hypotheses in
silico to identify better therapeutic targets with higher
confidence.
ETX's proprietary RNAi Platform enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by ETX's Computational Biology
Platform. The focus on hepatocytes offers the opportunity to work
across a wide variety of diseases. The liver is a highly
metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of
action.
ETX is progressing a pipeline of first-in-class pre-clinical
RNAi candidates in several therapeutic areas including haematology,
cardiovascular disease and non-alcoholic steatohepatitis ("NASH").
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. e-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFLELVISIIV
(END) Dow Jones Newswires
January 04, 2023 10:15 ET (15:15 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024